Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Taiwan ETF (EWT) Price & Performance

Bristol-Myers Squibb CoTrade
iShares MSCI Taiwan ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares MSCI Taiwan ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.85 (market cap $129.94B), while iShares MSCI Taiwan ETF trades at $106.31. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals.

BMYEWT
Market Cap
$129.94B
Sector
HealthBroad Market / Factor
52-Week High
$65.89$111.53
52-Week Low
$42.60$58.05
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

iShares MSCI Taiwan ETF

EWT, the iShares MSCI Taiwan ETF, trades at $106.50, up 4.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is heavily concentrated in Taiwan's technology sector, particularly semiconductors like TSMC, benefiting from AI-driven demand. Recent news highlights strong performance in 2026, with gains near 50%, though foreign outflows in July indicate some rotation away from AI-heavy markets.

Outlook remains positive due to Taiwan's critical role in AI semiconductor supply chains, but risks include geopolitical tensions with China, market concentration, and volatility from foreign capital flows. Analyst sentiment is generally bullish, citing growth-adjusted valuations and resilient fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT